首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1547891

全球呼吸道疾病疫苗市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Respiratory Disease Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球呼吸系統疾病疫苗市場需求預計將從2023年的946.5億美元達到近1,133.2億美元的市場規模，2024-2032年研究期間複合年成長率為2.02%。

呼吸系統疾病是指攻擊呼吸系統（包括肺部和其他部位）的疾病。呼吸道疾病最常見的原因是細菌和病毒感染。其他原因包括空氣污染和吸煙。呼吸道疾病包括肺炎（細菌性、病毒性）、流感、慢性阻塞性肺病（COPD）、氣喘、肺癌和肺纖維化。疫苗接種被認為是對抗傳染病最安全的方法。單一疫苗或疫苗組合應該對此類疾病有效。

市場動態

全球市場的主要動力包括呼吸系統疾病盛行率的上升和慢性阻塞性肺病的增加。政府組織正在支持疫苗生產，以此作為預防呼吸道疾病的一步。大量呼吸道疾病疫苗正在研發中，並在全世界進行臨床試驗。主要市場參與者正在投資研發以開發功效增強的疫苗。所有因素加在一起預計將提振市場。 COVID-19 大流行是由 SARS-COV-2 病毒引起的呼吸道疾病。目前，世界上還沒有可以治癒該疾病的抗病毒藥物或疫苗。全球許多製藥組織正在努力儘早開發疫苗。由於需求龐大，預計此次大流行將快速推動全球呼吸道疾病市場的發展。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球呼吸道疾病疫苗市場的各個細分市場進行了包容性評估。呼吸道疾病疫苗產業的成長和趨勢為本研究提供了整體方法。

市場區隔

呼吸道疾病疫苗市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

病毒疫苗
細菌疫苗
聯合疫苗

按年齡段

兒科
成人

透過感染

新冠肺炎
流感
呼吸道合胞病毒 (RSV)
肺炎
其他

按配銷通路

醫院和零售藥房
政府供應商
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲呼吸道疾病疫苗市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。呼吸道疾病疫苗市場的主要參與者包括葛蘭素史克公司、強生服務公司、輝瑞公司、賽諾菲、印度血清研究所。 Ltd.、Sinovac、Bavarian Nordic、Merck & Co. Inc.、AstraZeneca、Emergent、Novavax、INOVIO Pharmaceuticals、Moderna Inc.。合作夥伴關係、財務概覽、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按類型分類的市場吸引力分析
- 按年齡層別分類的市場吸引力分析
- 按感染情況進行的市場吸引力分析
- 按配銷通路分類的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球呼吸系統疾病疫苗市場分析：按類型

按類型概述
歷史和預測數據
按類型分析
病毒疫苗
細菌疫苗
聯合疫苗

第 6 章：全球呼吸系統疾病疫苗市場分析：按年齡層別分類

按年齡層別概述
歷史和預測數據
按年齡層分析
兒科
成人

第 7 章：全球呼吸道疾病疫苗市場分析：依感染狀況

按感染概述
歷史和預測數據
按感染情況分析
新冠肺炎
流感
呼吸道合胞病毒 (RSV)
肺炎
其他

第 8 章：全球呼吸道疾病疫苗市場分析：按分銷管道

配銷通路概述
歷史和預測數據
按配銷通路分析
醫院和零售藥房
政府供應商
其他

第 9 章：全球呼吸道疾病疫苗市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 10 章：呼吸道疾病疫苗公司的競爭格局

呼吸系統疾病疫苗市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

頂級公司市佔率分析
市場集中度
GSK Plc.

公司概況
公司收入
產品
最新動態

Johnson & Johnson Services Inc.

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

Serum Institute Of India Pvt. Ltd.

公司概況
公司收入
產品
最新動態

Sinovac

公司概況
公司收入
產品
最新動態

Bavarian Nordic

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

Emergent

公司概況
公司收入
產品
最新動態

Novavax

公司概況
公司收入
產品
最新動態

INOVIO Pharmaceuticals

公司概況
公司收入
產品
最新動態

Moderna Inc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11212585

The global demand for Respiratory Disease Vaccine Market is presumed to reach the market size of nearly USD 113.32 Billion by 2032 from USD 94.65 Billion in 2023 with a CAGR of 2.02% under the study period 2024-2032.

Respiratory diseases are the diseases that attack the respiratory system, including lungs and the other parts. The most common causes of respiratory diseases are bacterial and viral infections. Other reasons include air pollution and smoking. Respiratory diseases include pneumonia (bacterial, viral), influenza, chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Vaccination is considered to be the safest way to fight infectious diseases. A single vaccine or combination of vaccines is supposed to be effective against such diseases.

MARKET DYNAMICS

The prime movers of the global market include the rising prevalence of respiratory disorders, increasing chronic obstructive pulmonary disease. Government organizations are supporting vaccine production as a step forward to prevent respiratory diseases. A large number of respiratory disease vaccines are in the pipeline, and undergoing clinical trials in the entire world. The key market players are investing in R & D to develop vaccines with enhanced efficacy. All the factors altogether are expected to boost the market. COVID-19 pandemic is a respiratory disease caused SARS-COV-2 virus. Currently, there is no antiviral drug or vaccine available in the world to cure the disease. A large number of pharmaceutical organizations across the globe are working strenuously to develop the vaccine at the earliest. The pandemic is expected to drive the global respiratory disease market at a fast pace owing to massive demand.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Respiratory Disease Vaccine. The growth and trends of Respiratory Disease Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Respiratory Disease Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Viral Vaccine
Bacterial Vaccine
Combination Vaccine

By Age Group

Pediatric
Adult

By Infection

COVID-19
Influenza
Respiratory Syncytial Virus (RSV)
Pneumonia
Others

By Distribution Channel

Hospital & Retail Pharmacies
Government Suppliers
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Respiratory Disease Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Respiratory Disease Vaccine market include GSK Plc., Johnson & Johnson Services Inc., Pfizer Inc., Sanofi, Serum Institute Of India Pvt. Ltd., Sinovac, Bavarian Nordic, Merck & Co. Inc., AstraZeneca, Emergent, Novavax, INOVIO Pharmaceuticals, Moderna Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RESPIRATORY DISEASE VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Infection
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Viral Vaccine Historic and Forecast Sales By Regions
5.5. Bacterial Vaccine Historic and Forecast Sales By Regions
5.6. Combination Vaccine Historic and Forecast Sales By Regions

6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY AGE GROUP

6.1. Overview By Age Group
6.2. Historical and Forecast Data
6.3. Analysis By Age Group
6.4. Pediatric Historic and Forecast Sales By Regions
6.5. Adult Historic and Forecast Sales By Regions

7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY INFECTION

7.1. Overview By Infection
7.2. Historical and Forecast Data
7.3. Analysis By Infection
7.4. COVID-19 Historic and Forecast Sales By Regions
7.5. Influenza Historic and Forecast Sales By Regions
7.6. Respiratory Syncytial Virus (RSV) Historic and Forecast Sales By Regions
7.7. Pneumonia Historic and Forecast Sales By Regions
7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital & Retail Pharmacies Historic and Forecast Sales By Regions
8.5. Government Suppliers Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RESPIRATORY DISEASE VACCINE COMPANIES

10.1. Respiratory Disease Vaccine Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF RESPIRATORY DISEASE VACCINE INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. GSK Plc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Johnson & Johnson Services Inc.
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Pfizer Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Sanofi
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Serum Institute Of India Pvt. Ltd.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Sinovac
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Bavarian Nordic
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Merck & Co. Inc.
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. AstraZeneca
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Emergent
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Novavax
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments
11.14. INOVIO Pharmaceuticals
- 11.14.1 Company Overview
- 11.14.2 Company Revenue
- 11.14.3 Products
- 11.14.4 Recent Developments
11.15. Moderna Inc
- 11.15.1 Company Overview
- 11.15.2 Company Revenue
- 11.15.3 Products
- 11.15.4 Recent Developments